BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//BioCatalystFeed//bcf//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:BioCatalystFeed VNDA catalysts
X-WR-CALDESC:Scheduling/reference data from public records\; dates can move
 . Not investment\, legal or medical advice.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:22a34d40e4d301c9983c@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:VNDA P3 readout (est.): Study to Evaluate the Efficacy and Safety o
 f VQW-765 for the On-Demand Treatment of Social Anxiety Disorder
DESCRIPTION:Study to Evaluate the Efficacy and Safety of VQW-765 for the On
 -Demand Treatment of Social Anxiety Disorder\nNCT07221578 | PHASE3 | ACTIV
 E_NOT_RECRUITING | sponsor: Vanda Pharmaceuticals\nPrimary completion date
  (ESTIMATED)\; top-line results usually follow later.\nDate precision: mon
 th (shown on the first day)\nTicker VNDA (confidence 0.9)\nSource: https:/
 /clinicaltrials.gov/study/NCT07221578\nScheduling/reference data from publ
 ic records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07221578
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:5fbf684e2aa8144defc3@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:VNDA P3 readout (est.): A Study to Evaluate Tradipitant on Treating
  Nausea and Vomiting Induced by GLP-1R Agonist Use
DESCRIPTION:A Study to Evaluate Tradipitant on Treating Nausea and Vomiting
  Induced by GLP-1R Agonist Use\nNCT07446439 | PHASE3 | RECRUITING | sponso
 r: Vanda Pharmaceuticals\nPrimary completion date (ESTIMATED)\; top-line r
 esults usually follow later.\nTicker VNDA (confidence 0.9)\nSource: https:
 //clinicaltrials.gov/study/NCT07446439\nScheduling/reference data from pub
 lic records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07446439
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:f6b2e9cda2fe8dfb571e@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20261212
DTEND;VALUE=DATE:20261213
SUMMARY:VNDA PDUFA (company-disclosed): imsidolimab
DESCRIPTION:PDUFA December 12\, 2026 - Vanda Pharmaceuticals Inc. (imsidoli
 mab)\nConfidence: company-disclosed\nTicker VNDA (confidence 1.0)\nSource:
  https://www.sec.gov/Archives/edgar/data/1347178/000162828026053308/vnda8-
 k852026exhibit991.htm\nScheduling/reference data from public records\; dat
 es can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.sec.gov/Archives/edgar/data/1347178/000162828026053308/vnda
 8-k852026exhibit991.htm
CATEGORIES:pdufa,company-disclosed
END:VEVENT
BEGIN:VEVENT
UID:253fefd9948e88080a93@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260220
DTEND;VALUE=DATE:20260221
SUMMARY:VNDA APPROVAL: BYSANTI
DESCRIPTION:Approved 2026-02-20: BYSANTI (NDA220358 ORIG1)\nConfidence: con
 firmed\nTicker VNDA (confidence 0.6)\nSource: https://www.accessdata.fda.g
 ov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=220358\nSchedu
 ling/reference data from public records\; dates can move. Not investment\,
  legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=220358
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:86ebdf81aa6afc446bc5@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20251230
DTEND;VALUE=DATE:20251231
SUMMARY:VNDA APPROVAL: NEREUS
DESCRIPTION:Approved 2025-12-30: NEREUS (NDA220152 ORIG1)\nConfidence: conf
 irmed\nTicker VNDA (confidence 0.6)\nSource: https://www.accessdata.fda.go
 v/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=220152\nSchedul
 ing/reference data from public records\; dates can move. Not investment\, 
 legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=220152
CATEGORIES:approval,confirmed
END:VEVENT
END:VCALENDAR
